Wide Ranks

ADAG

Adagene Inc.

2.31

Top Statistics
Market Cap 102 M Forward PE -2.98 Revenue Growth 0.00 %
Current Ratio 2.50 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.47 Enterprise / Revenue 64.91 Price To Sales Trailing12 Months 125.36
Profitability
Profit Margins 0.00 % Operating Margins -4534.83 %
Balance Sheet
Total Cash 95 M Total Cash Per Share 1.73 Total Debt 20 M
Total Debt To Equity 36.74 Current Ratio 2.50 Book Value Per Share 1.28
All Measures
Short Ratio 2.00 % Message Board Id finmb_118162960 Shares Short Prior Month 21352
Return On Equity -0.4570 City Suzhou Uuid 62e74ad1-53ab-3c04-9114-3e2ec68862ec
Previous Close 2.28 First Trade Date Epoch Utc 1 B Book Value 1.28
Beta 0.5770 Total Debt 20 M Volume 31895
Price To Book 1.81 Fifty Two Week Low 1.35 Total Cash Per Share 1.73
Total Revenue 815746 Shares Short Previous Month Date 1 B Target Median Price 4.90
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Operating Margins -4534.83 % Target Mean Price 8.03 Net Income To Common -31849280
Implied Shares Outstanding 55 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 33720 Average Volume10days 33720 Total Cash 95 M
Next Fiscal Year End 1 B Revenue Per Share 0.0190 Held Percent Insiders 0.1066
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.28 Target Low Price 3.50 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.47 Open 2.29 Free Cashflow -16924380
Dividend Yield 0.00 % Return On Assets -0.1959 Time Zone Short Name EST
Trailing Eps -0.7300 Day Low 2.15 Address1 Building C14
Shares Outstanding 44 M Price Hint 4 Target High Price 18.81
Website https://www.adagene.com 52 Week Change 0.3200 Average Volume 63468
Forward Eps -0.6900 Recommendation Key buy Quick Ratio 242.20 %
Is_sp_500 False Regular Market Day High 2.50 Profit Margins 0.00 %
Debt To Equity 36.74 Fifty Two Week High 4.38 Day High 2.50
Shares Short 1514 Regular Market Open 2.29 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 64.91 Revenue Growth 0.00 %
Operating Cashflow -28401280 Currency USD Time Zone Full Name America/New_York
Market Cap 102 M Is_nasdaq_100 False Zip 215123
Quote Type EQUITY Industry Biotechnology Long Name Adagene Inc.
Regular Market Day Low 2.15 Held Percent Institutions 0.2520 Current Price 2.31
Address2 4th Floor No. 218, Xinghu Street Suzhou Industrial Park Enterprise To Ebitda -1.47 Financial Currency USD
Current Ratio 2.50 Gross Margins 100.00 % Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country China Float Shares 19 M
Two Hundred Day Average 2.68 Enterprise Value 52 M Price To Sales Trailing12 Months 125.36
Forward PE -2.98 Regular Market Volume 31895 Ebitda -36131064
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.

The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.

It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs.

The company was incorporated in 2011 and is headquartered in Suzhou, China.